The clinical trial of UGN-102 for low grade intermediate risk non-muscle-invasive bladder cancer (ENVISION)

UroGen Pharma Ltd is recruiting patients for the clinical trial of A Phase 3 Single-Arm Study of UGN-102 for Treatment of Low Grade Intermediate Risk Non-Muscle-Invasive Bladder Cancer (ENVISION).

This Phase 3, multinational, single-arm, multicenter study will evaluate the efficacy and safety of UGN-102 as primary chemoablative therapy in patients with low grade intermediate risk non-muscle-invasive bladder cancer (LG IR NMIBC).

The page dedicated to this clinical trial can be found here: https://ichgcp.net/clinical-trials-registry/NCT05243550.

Clinical Research News

Considerations for the Use of Real-World Data and Real-World Evidence To Support Regulatory Decision-Making for Drug and Biological Products
Submission of comments on ICH E6 (R3) Guideline for Good Clinical Practice(GCP) - Step 2b 
ICH E6(R3) Good Clinical Practice guidance - Step 2 Public Consultation
The study of the new investigational drug for acute myeloid leukemia and myelodysplastic syndrome
Open Label study of entrectinib in ROS1 gene fusion-positive rare adult, paediatric and teenage/young adult cancers
Gasherbrum Bio, Inc is starting the study of GSBR-1290 drug in overweight or obese healthy adults
A new study of Dexpramipexole in adolescents and adults with severe Eosinophilic Asthma

Upcoming Clinical Trials

The clinical trial of UGN-102 for low grade intermediate risk non-muscle-invasive bladder cancer (ENVISION)

All jobs

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe